Trial Profile
An open, longitudinal real life study to demonstrate the glycemic control, weight and body composition changes with the use of Exenatide LAR/Dapagliflozin combination in Obese Type 2 Diabetes Patients in Mexico
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2018 New trial record